Article

Pharmaceutical Executive

Outlook: Market Access in Australia

Despite recent challenges, the Australian market still offers a number of opportunities for pharma manufacturers.

Australia is a country that has challenged pharmaceutical manufacturers in recent years with extensive government reforms in drug pricing, unpredictability around reimbursement and pricing decisions, and other structural changes. Despite these challenges, the Australian market still offers a number of opportunities for manufacturers.

This BioPharmaceutical International article by Michael J. Kuchenreuther and Jill E. Sackman looks at those opportunities.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Arda Ural
Lynlee Brown
Arda Ural
Related Content
Credit: zimmytws | stock.adobe.com. Balancing profitability with affordability, redesigning supply chains for resilience, and engaging actively in trade policy discussions are no longer optional, they are strategic imperatives.
August 3rd 2025

How Can Pharma Leadership Prepare for the Current Tariff Environment and Potential Changes in 2026?

Thani Jambulingam, PhD
The 15% tariff on pharmaceutical imports from the European Union is not a short term inconvenience, it represents a structural shift in the economics of the US pharmaceutical market.
President Donald Trump
August 3rd 2025

President Trump Issues Letters to 17 Major Pharma Companies Demanding Action on Most-Favored-Nation Order

Mike Hollan
The letter states that the companies have 60 days to meet the President's requirements.
Stock.adobe.com
August 3rd 2025

Developing the CAR-T Sector in Saudi Arabia

Mike Hollan
Jeff Liter, CEO of Luminary, discusses his company’s approach to CAR-T therapies and why the developing Saudi market has potential.
UAE flag waving in the sky, national symbol of UAE | Image Credit: © Freelancer - stock.adobe.com
August 3rd 2025

Abu Dhabi Reinforces Global Leadership in Healthcare Innovation with High-Level US Visit

Patrick Lavery
During a high-level US visit, the Department of Health—Abu Dhabi signed strategic agreements with Abbott, Boehringer Ingelheim, and Sanofi to boost pharmaceutical manufacturing, expand vaccine development, and advance digital health and clinical research.
China’s Trial Advantage: Tracking Nation’s Growth in Pharma Innovation and Global Investment
August 3rd 2025

China’s Trial Advantage: Tracking Nation’s Growth in Pharma Innovation and Global Investment

Bruce Liu Martin Slusarczyk, PhD Selene Peng Jonathan Welte
A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.
Stock.adobe.com
August 3rd 2025

WHO Foundation Launches Emergency Fundraising for Measles and Rubella Network

Mike Hollan
The GMRLN plays an important role in identifying outbreaks early and providing the necessary support to control them.